Close Menu

NEW YORK – Ginkgo Bioworks said on Friday that it is collaborating with New Jersey-based diagnostics firm Access Bio on rapid antigen tests for COVID-19.

Boston-based Ginkgo said that it is providing Access Bio with an undisclosed amount of funding to expand manufacturing capacity for the tests. In addition, Ginkgo will offer at least 10 million of the antigen test kits through its Concentric by Ginkgo service, which provides end-to-end testing for organizations, including antigen and PCR-based tests.

Terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.